Gene therapy to regenerate heart tissue in patients with heart failure
Triple Gene Therapy for Ischemic Heart Failure
This study is exploring a new way to help people with ischemic heart failure by using a mix of three gene therapies that aim to heal the heart and improve its function, and patients may have the chance to participate in trials to see how well this treatment works.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11040424 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treat ischemic heart failure by using a combination of three gene therapies aimed at regenerating heart tissue. The therapies focus on inducing the proliferation of heart cells, reprogramming existing fibroblasts into heart cells, and enhancing blood vessel formation in the heart. By testing these therapies together, the research aims to provide a comprehensive solution to restore heart function. Patients may be involved in clinical trials to evaluate the safety and effectiveness of this combined treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults over 21 years old who have been diagnosed with ischemic heart failure.
Not a fit: Patients with heart failure due to non-ischemic causes or those who are not eligible for gene therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that restores heart function in patients suffering from ischemic heart failure.
How similar studies have performed: Previous studies have shown promising results with individual gene therapies for heart regeneration, but this combined approach is novel and has not been extensively tested.
Where this research is happening
Houston, United States
- Baylor College of Medicine — Houston, United States (Active)
Researchers
- Principal investigator: Mohamed, Tamer M a — Baylor College of Medicine
- Study coordinator: Mohamed, Tamer M a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.